4 April 2018 - - The US Food and Drug Administration has granted orphan drug designation to Daejeon, South Korea-based clinical-stage biotech company PharmAbcine Inc.'s leading clinical compound TTAC-0001 for treatment of glioblastoma multiforme (GBM), the company said.
TTAC-0001, an investigational therapy, is a highly selective and potent anti-VEGFR2 (KDR/flk-1) mAb in clinical development for recurrent GBM (rGBM) indications.
VEGFR2 is over-expressed in most malignant tumors, and this signaling pathway is a key regulator for tumor angiogenesis.
PharmAbcine develops fully human therapeutic antibody and next generation multispecific antibody therapeutics based on in-house developed novel platform, DIG-Body, PIG-Body and TIG-Body for the treatment of human diseases, such as cancer and inflammatory diseases.